Search Results
Your search for ,dUe matches 5445 pages
Showing 2901 - 2950Pioneer in Genitourinary Oncology, José R. Germà-Lluch, MD, PhD, Sheds Light on Treating Rare Tumors
“At the age of 6, my mother threw me into the arms of Hippocrates’ discipline, giving me as a special gift a toy suitcase full of medical equipment and a little puppet to train my skills with a stethoscope, syringe, thermometer, small reflex hammer, and torch to explore the oropharyngeal airways....
Husband and Wife Leave a Giant Legacy in Oncology
The remarkable careers of Jimmie C. Holland, MD, and James F. Holland, MD, spanned collectively for more than a century, leaving an indelible footprint in oncology clinical care and research. Synonymous with cancer care itself, the Hollands were a living documentary of the rich and dramatic history ...
Pioneering Researcher and Oncologist Volker S. Diehl, MD, Helped Unlock the ‘Black Box’ of Hodgkin Lymphoma
Volker S. Diehl, MD, the internationally renowned hematologist and researcher, was born in Berlin, Germany, on February 28, 1938—arguably one of the most tumultuous periods in world history. Germany had just invaded Austria, signaling the dark intentions of the Third Reich. In 1943, the air raids...
Treatment of Malignant Pleural Mesothelioma: ASCO Clinical Practice Guideline
As reported by Hedy L. Kindler, MD, of the University of Chicago, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of malignant pleural mesothelioma.1 The guideline was based on a systematic literature search and expert panel...
Closing the Gap in Oncology Care for Adolescents and Young Adults
During her presentation “Adolescent and Young Adult Survivorship: What Do We Still Need to Know?” at the 2017 Cancer Survivorship Symposium: Advancing Care and Research, Emily S. Tonorezos, MD, MPH, a general internist in the Adult Long-Term Follow-Up Program at Memorial Sloan Kettering Cancer...
Update on ATLAS Trial of Axitinib for RCC Recurrence Risk
Pfizer recently announced that the independent data monitoring committee for the phase III ATLAS trial, which is evaluating axitinib (Inlyta) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy, recommended stopping the trial at a planned interim...
Monica M. Bertagnolli, MD, FASCO, a Cattle Rancher’s Daughter, Becomes ASCO President
ASCO President-Elect Monica M. Bertagnolli, MD, FASCO, was born and reared in Wyoming, where her family ran a cattle ranch in the foothills of the snow-topped peaks of the Wind River Range (or “Winds” for short), a place of breathtakingly uncluttered vistas where the chief feature is the air...
Brentuximab Vedotin in Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
On March 20, 2018, brentuximab vedotin (Adcetris) was approved for the treatment of adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.1,2 Supporting Efficacy Data Approval was based on the findings of the open-label phase III...
Tisagenlecleucel for Adults With Relapsed or Refractory Large B-Cell Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 1, 2018, tisagenlecleucel (Kymriah), a...
Weighing the Cost and Value of CAR T-Cell Therapy
This past year’s approval by the U.S. Food and Drug Administration (FDA) of two chimeric antigen receptor (CAR) T-cell therapies heralded a new era in both effective cancer treatments and the most expensive cancer drugs ever. Tisagenlecleucel (Kymriah) was initially approved for the treatment of...
ASCO Clinical Practice Guideline on Managing Immune-Related Adverse Events: Next Big Step for Immune Checkpoint Inhibitors
The publication of the ASCO clinical practice guideline for the management of immune therapy–related adverse events—reviewed in this issue of The ASCO Post—represents an important next step in the incorporation of checkpoint blocking antibodies as standard cancer treatment modalities.1 The U.S....
ASCO Clinical Practice Guideline: Management of Immune-Related Adverse Events From Immune Checkpoint Inhibitor Therapy
As reported in the Journal of Clinical Oncology by Julie R. Brahmer, MD, of Johns Hopkins Kimmel Cancer Center, and colleagues, ASCO has released a clinical practice guideline on management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy.1 Immune...
New Data on ALK Inhibitors and CAR T-Cell Therapies
The 2018 American Association for Cancer Research (AACR) Annual Meeting was abuzz with more than 22,000 attendees from around the world who came to Chicago to hear the latest in basic science and clinical trial results. Here we present summaries of a few of the highlights from the AACR meeting...
The Pharmacist’s Role in Educating the Health-Care Team About Adverse Effects of Immune Checkpoint Inhibitors
Named by ASCO as Advance of the Year for both 2016 and 2017,1 and with more than 10 U.S. Food and Drug Administration–approved indications—and more on the way—it’s safe to say the era of cancer immunotherapy is upon us. To prepare, physicians must understand not only which patients will benefit,...
Early Research May Unlock How Pancreatic Cancer Metastasizes to the Liver
Douglas Fearon, MD, Professor at Cold Spring Harbor Laboratory, and colleagues may have discovered how pancreatic cancer metastasizes to the liver following surgery, as reported by Pommier et al in Science. “This discovery is significant because for patients who undergo pancreatic cancer...
For Adjuvant Trastuzumab, 6 Months Is Noninferior to 12 Months
The noninferiority phase III Persephone trial could shake up the standard of care for adjuvant trastuzumab (Herceptin), showing that patients with early-stage HER2-positive breast cancer derived as much benefit from 6 months of trastuzumab as 12 months, according to research from the United Kingdom ...
Oxybutynin for Androgen Deprivation–Associated Hot Flashes in Prostate Cancer
In a letter to the editor of The New England Journal of Medicine, Smith et al describe successful use of oxybutynin to treat hot flashes in a patient receiving androgen-deprivation therapy (ADT) for prostate cancer. As noted by the authors, nonhormonal treatments for menopausal hot flashes in women ...
ASCO and ABIM Announce Collaboration on Maintenance of Certification Pathway
ASCO and the American Board of Internal Medicine (ABIM) have announced that they are working to co-create a pathway to provide doctors with a flexible way to maintain board certification. Beginning in 2020, oncologists will be able to choose from two different assessment pathways. They may take an ...
Rivaroxaban May Reduce Risk of Venous Thromboembolism in Patients With Cancer
Patients with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE)—either deep-vein thrombosis (DVT) or pulmonary embolism (PE). Although there are many causes and risk factors for VTE, patients with cancer are...
USPSTF Recommendations on PSA-Based Screening for Prostate Cancer
As reported in JAMA, the US Preventive Services Task Force (USPSTF) has issued updated recommendations on prostate-specific antigen (PSA)-based screening for prostate cancer. To inform the recommendations, the USPSTF reviewed evidence on benefits and harms of PSA-based screening and treatment of...
2018 ASCO: Shortening Adjuvant Trastuzumab to 6 Months in Patients With HER2-Positive Early Breast Cancer Is Effective and Reduces Cardiac Toxicities
Persephone, a large phase III randomized noninferiority study conducted in the United Kingdom comparing 6 months to 12 months of trastuzumab (Herceptin) in patients with HER2-positive early breast cancer has found 6 months of trastuzumab to be noninferior to 12 months of the therapy. In addition,...
2018 ASCO: Upfront, Comprehensive Genetic Testing in Advanced Lung Cancer Is Cost-Effective
An economic model comparing different types of genetic testing in metastatic non–small cell lung cancer (NSCLC) found that using next-generation sequencing to test for all known lung cancer–related gene changes at the time of diagnosis was more cost-effective and faster than testing one ...
2018 ASCO: Majority of Heavy Smokers Not Screened for Lung Cancer, Despite USPSTF Recommendations
An analysis of 1,800 lung cancer screening sites nationwide found that only 1.9% of more than 7 million current and former heavy smokers were screened for lung cancer in 2016, despite U.S. Preventive Services Task Force (USPSTF) and ASCO screening recommendations. Results from this study—the...
Dose-Dense Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Iyer et al found that dose-dense neoadjuvant gemcitabine plus cisplatin produced a high response rate and was generally well tolerated in patients with planned radical cystectomy for muscle-invasive bladder cancer. Study Details In ...
Racial/Ethnic Disparities in the Quality of End-of-Life Care Among Patients With Lung Cancer
Significant disparities in the quality of end-of-life lung cancer care were found among racial/ethnic minorities, with higher odds of experiencing potentially preventable medical encounters during end of life as compared with non-Hispanic whites. These findings were published by Karanth et al in...
Updated ASCO/SSO Guideline on Sentinel Lymph Node Biopsy in Melanoma: Addressing Fundamental Clinical Questions
Dr. Thompson is Professor of Melanoma and Surgical Oncology, Sydney Medical School, The University of Sydney, and Senior Surgeon, Melanoma Institute Australia, Sydney. IN THE MID-1990s, the surgical management of patients presenting with primary cutaneous melanomas changed forever when the...
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: ASCO/SSO Clinical Practice Guideline Update
AS REPORTED IN the Journal of Clinical Oncology by Sandra L. Wong, MD, of Dartmouth-Hitchcock Medical Center, and colleagues, ASCO and the Society of Surgical Oncology (SSO) have issued an update to the ASCO/SSO clinical practice guideline on sentinel lymph node biopsy and management of regional...
Follow-up Too Short in Ovarian Cancer, Too Long in Other Gynecologic Malignancies
A STANDARDIZED 5-year period of surveillance by a gynecologic oncologist was found to be inadequate for some gynecologic cancers and excessive for others, according to research presented by Robert Dood, MD, of The University of Texas MD Anderson Cancer Center, Houston, at the 2018 Society of...
NCCN Debuts Three New Sets of Guidelines
THE NATIONAL Comprehensive Cancer Network® (NCCN®) debuted three sets of completely new guidelines for treating patients with uveal melanoma, for treating patients who have cancer and the human immunodeficiency virus (HIV), and for managing immune-related toxicities. Cancer in People Living With...
Minimal Residual Disease in Acute Myeloid Leukemia: Mutation Matters
A RECENT article in The New England Journal of Medicine explored the nuances of minimal/measurable residual disease testing after induction treatment of acute myeloid leukemia (AML)1 and David P. Steensma, MD, and Benjamin L. Ebert, MD, PhD, of Dana-Farber Cancer Institute and Harvard Medical...
Pembrolizumab Plus Standard Chemotherapy Improves Survival in Newly Diagnosed Metastatic Non–Small Cell Lung Cancer
ADDING THE IMMUNE checkpoint inhibitor pembrolizumab (Keytruda) to standard chemotherapy with pemetrexed (Alimta) and a platinum as first-line therapy was superior to chemotherapy alone in the KEYNOTE-189 trial.1 Induction and maintenance therapies with the new triplet therapy improved overall...
Study Finds Desmoplastic Melanoma Highly Responsive to PD-1/PD-L1 Blockade
Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients. Treatment is difficult, as these tumors are often resistant to chemotherapy and lack actionable mutations commonly found in other types of...
Spring
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Chamomile
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, focus attention on chamomile ...
Editor’s Note: FDA Response to Comments by Dr. Steven E. Vogl
In 2011, the U.S. Food and Drug Administration (FDA) convened an advisory committee that recognized metastasis-free survival as a clinically relevant endpoint for nonmetastatic prostate cancer due to shorter trial readout times and acknowledgment that a substantial delay in the transition to a...
Nilotinib Label Updated to Provide Treatment Discontinuation Recommendations for CML With Sustained Molecular Response
On December 22, 2017, the product label for nilotinib (Tasigna) was updated to include information on nilotinib discontinuation, postdiscontinuation monitoring, and guidance for treatment reinitiation in patients with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) who have...
Combined Immune Checkpoint and VEGF Inhibition as First-Line Therapy in Advanced Clear Cell Kidney Cancer
In a dose-finding, dose-expansion phase Ib trial (JAVELIN Renal 100) reported in The Lancet Oncology, Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and colleagues determined the maximum tolerated dose of the immune checkpoint inhibitor avelumab (Bavencio)...
FDA Grants Orphan Drug Designation to BN-Brachyury for the Treatment of Chordoma
On May 2, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to the cancer vaccine BN-Brachyury for the treatment of chordoma. Chordoma is a rare type of cancer that develops along the spine, with presentation occurring at one of three main sites: sacrum, mobile spine, or...
Men With Nonmelanoma Skin Cancer History May Have Reduced Risk of Death From Melanoma
Skin cancer survivors know firsthand that the disease is most treatable when detected early, so they’re more likely to be vigilant about skin exams—and new research shows that such vigilance pays off. After studying more than 900 cases of melanoma reported through the Health...
Diagnosis-to-Treatment Interval and Outcome in Newly Diagnosed DLBCL
In a study reported in the Journal of Clinical Oncology, Maurer et al found that a shorter interval between diagnosis and treatment was associated with adverse prognostic features and that a longer interval was associated with greater event-free survival in the first-line treatment of diffuse large ...
ESTRO 37: Brachytherapy for Patients With Cervical Cancer Does Not Increase Risk of Ureteral Stricture
A rare but potentially serious complication following radiation treatment for cervical cancer is a narrowing of the tube that takes urine from the kidneys to the bladder (the ureter), which can lead to kidney damage and sometimes life-threatening infections. This is called ureteral stricture and,...
Long-Term Outcomes of Adjuvant Treatment in High-Risk Prostate Cancer
As reported by Hussain et al in the Journal of Clinical Oncology, long-term follow-up of the phase III SWOG S9921 trial showed that the addition of adjuvant mitoxantrone and prednisone (MP) to androgen-deprivation therapy (ADT) did not improve survival and increased death from other malignancies in ...
Immune-Related Toxicity With Combination Immunotherapy for Melanoma
As reported in JAMA Oncology by Alexander N. Shoushtari, MD, of the Memorial Sloan Kettering Cancer Center, and colleagues, a single-center experience has shown a very high rate of clinically significant immune-related adverse events with nivolumab (Opdivo) plus ipilimumab (Yervoy) for advanced...
Massage Therapy for Patients With Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, reviews the current data on the use of massage to...
Updated International Myeloma Working Group Criteria: Diagnostic Challenges
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Landgren review the underlying data that shaped the updated International Myeloma Working Group (IMWG) diagnostic criteria for...
Adjuvant FOLFOX or CAPOX for 3 or 6 Months in Stage II or III Colon Cancer
As reported in the Journal of Clinical Oncology by Sobrero et al, the Italian phase III TOSCA trial did not demonstrate noninferiority of 3 vs 6 months of adjuvant CAPOX (capecitabine plus oxaliplatin) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) in relapse-free survival in stage II or...
Update on ATLAS Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Pfizer recently announced that the independent data monitoring committee for the phase III ATLAS trial, which is evaluating axitinib (Inlyta) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy, recommended stopping the trial at a planned interim...
Use of Indwelling Pleural Catheter for Outpatient Talc Administration in Treatment of Malignant Pleural Effusion
In a UK study reported in The New England Journal of Medicine, Bhatnagar et al found that outpatient talc vs placebo administration via indwelling pleural catheter was associated with a higher rate of pleurodesis in patients with malignant pleural effusion. Study Details In the study, a target of ...
Nut Consumption in Patients With Stage III Colon Cancer
People with stage III colon cancer who regularly eat tree nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t, according to findings published by Fadelu et al in the Journal of Clinical Oncology.1 Study Findings The study followed 826 participants in the...
AACR 2018: New Liquid Biopsy–Based Cancer Model Reveals Data on Chemoresistance in SCLC
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for...
